201 related articles for article (PubMed ID: 32024754)
1. TIP5 primes prostate luminal cells for the oncogenic transformation mediated by
Pietrzak K; Kuzyakiv R; Simon R; Bolis M; Bär D; Aprigliano R; Theurillat JP; Sauter G; Santoro R
Proc Natl Acad Sci U S A; 2020 Feb; 117(7):3637-3647. PubMed ID: 32024754
[TBL] [Abstract][Full Text] [Related]
2. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
[TBL] [Abstract][Full Text] [Related]
3. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
4. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
[No Abstract] [Full Text] [Related]
5. BAZ2A-mediated repression via H3K14ac-marked enhancers promotes prostate cancer stem cells.
Peña-Hernández R; Aprigliano R; Carina Frommel S; Pietrzak K; Steiger S; Roganowicz M; Lerra L; Bizzarro J; Santoro R
EMBO Rep; 2021 Nov; 22(11):e53014. PubMed ID: 34403195
[TBL] [Abstract][Full Text] [Related]
6. MEX3D is an oncogenic driver in prostate cancer.
Shao L; Wang J; Karatas O; Ittmann M
Prostate; 2021 Nov; 81(15):1202-1213. PubMed ID: 34455614
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional landscape of PTEN loss in primary prostate cancer.
Imada EL; Sanchez DF; Dinalankara W; Vidotto T; Ebot EM; Tyekucheva S; Franco GR; Mucci LA; Loda M; Schaeffer EM; Lotan T; Marchionni L
BMC Cancer; 2021 Jul; 21(1):856. PubMed ID: 34311724
[TBL] [Abstract][Full Text] [Related]
8. Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay.
Park JW; Lee JK; Phillips JW; Huang P; Cheng D; Huang J; Witte ON
Proc Natl Acad Sci U S A; 2016 Apr; 113(16):4482-7. PubMed ID: 27044116
[TBL] [Abstract][Full Text] [Related]
9. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer.
Ding Y; Li N; Dong B; Guo W; Wei H; Chen Q; Yuan H; Han Y; Chang H; Kan S; Wang X; Pan Q; Wu P; Peng C; Qiu T; Li Q; Gao D; Xue W; Qin J
J Clin Invest; 2019 Feb; 129(2):759-773. PubMed ID: 30496141
[TBL] [Abstract][Full Text] [Related]
10. Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathways.
Xing C; Ci X; Sun X; Fu X; Zhang Z; Dong EN; Hao ZZ; Dong JT
Neoplasia; 2014 Nov; 16(11):883-99. PubMed ID: 25425963
[TBL] [Abstract][Full Text] [Related]
11. LZTS2 and PTEN collaboratively regulate ß-catenin in prostatic tumorigenesis.
Yu EJ; Hooker E; Johnson DT; Kwak MK; Zou K; Luong R; He Y; Sun Z
PLoS One; 2017; 12(3):e0174357. PubMed ID: 28323888
[TBL] [Abstract][Full Text] [Related]
12. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.
Liu AJ; Furusato B; Ravindranath L; Chen YM; Srikantan V; McLeod DG; Petrovics G; Srivastava S
J Zhejiang Univ Sci B; 2007 Dec; 8(12):853-9. PubMed ID: 18257117
[TBL] [Abstract][Full Text] [Related]
14. Role of lncRNAs in prostate cancer development and progression.
Weiss M; Plass C; Gerhauser C
Biol Chem; 2014 Nov; 395(11):1275-90. PubMed ID: 25153594
[TBL] [Abstract][Full Text] [Related]
15. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
[TBL] [Abstract][Full Text] [Related]
16. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
[TBL] [Abstract][Full Text] [Related]
17. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence.
Gu L; Frommel SC; Oakes CC; Simon R; Grupp K; Gerig CY; Bär D; Robinson MD; Baer C; Weiss M; Gu Z; Schapira M; Kuner R; Sültmann H; Provenzano M; ; Yaspo ML; Brors B; Korbel J; Schlomm T; Sauter G; Eils R; Plass C; Santoro R
Nat Genet; 2015 Jan; 47(1):22-30. PubMed ID: 25485837
[TBL] [Abstract][Full Text] [Related]
18. A basal-enriched microRNA is required for prostate tumorigenesis in a Pten knockout mouse model.
Fan X; Bjerke GA; Riemondy K; Wang L; Yi R
Mol Carcinog; 2019 Dec; 58(12):2241-2253. PubMed ID: 31512783
[TBL] [Abstract][Full Text] [Related]
19. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045
[TBL] [Abstract][Full Text] [Related]
20. DGCR8 is essential for tumor progression following PTEN loss in the prostate.
Belair CD; Paikari A; Moltzahn F; Shenoy A; Yau C; Dall'Era M; Simko J; Benz C; Blelloch R
EMBO Rep; 2015 Sep; 16(9):1219-32. PubMed ID: 26206718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
